Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 molnupiravir studies
Outcomes in molnupiravir studies. There is substantial positive publication bias. Three trials (NCT04575584, CTRI/2021/05/033864, and CTRI/2021/08/0354242) have reported no significant efficacy, however the results have not been published yet.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 55% 5 2,724 Improvement, Studies, Patients Relative Risk, 95% CI Mortality 86% 2 1,610 Hospitalization 57% 2 943 Recovery 18% 2 759 Viral clearance 57% 2 527 RCTs 55% 5 2,724 Peer-reviewed 37% 2 759 Early 55% 5 2,724 Molnupiravir for COVID-19 c19mp.com Dec 3, 2021 Favors molnupiravir Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Merck (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tau​2 = 0.24; I​2 = 53.7% Early treatment 55% 0.45 [0.24-0.85] 54/1,407 129/1,317 55% improvement All studies 55% 0.45 [0.24-0.85] 54/1,407 129/1,317 55% improvement 5 molnupiravir COVID-19 studies c19mp.com Dec 3, 2021 Tau​2 = 0.24; I​2 = 53.7%; Z = 2.47 Effect extraction pre-specified Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] 0/140 1/62 Improvement, RR [CI] Treatment Control Merck (RCT) 89% 0.11 [0.01-0.86] 1/709 9/699 Tau​2 = 0.00; I​2 = 0.0% Early treatment 86% 0.14 [0.02-0.78] 1/849 10/761 86% improvement All studies 86% 0.14 [0.02-0.78] 1/849 10/761 86% improvement 2 molnupiravir COVID-19 mortality results c19mp.com Dec 3, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.25 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) -33% 1.33 [0.14-12.5] hosp. 3/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Tau​2 = 0.34; I​2 = 31.6% Early treatment 57% 0.43 [0.13-1.49] 10/511 24/432 57% improvement All studies 57% 0.43 [0.13-1.49] 10/511 24/432 57% improvement 2 molnupiravir COVID-19 hospitalization results c19mp.com Dec 3, 2021 Tau​2 = 0.34; I​2 = 31.6%; Z = 1.32 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Merck (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tau​2 = 0.00; I​2 = 0.0% Early treatment 74% 0.26 [0.12-0.55] 8/1,220 33/1,131 74% improvement All studies 74% 0.26 [0.12-0.55] 8/1,220 33/1,131 74% improvement 3 molnupiravir COVID-19 serious outcomes c19mp.com Dec 3, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 3.50 Effect extraction pre-specified Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hetero (RCT) 33% 0.67 [0.54-0.82] recov. time 371 (n) 370 (n) Improvement, RR [CI] Treatment Control Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Tau​2 = 0.13; I​2 = 54.4% Early treatment 18% 0.82 [0.44-1.52] 8/383 3/376 18% improvement All studies 18% 0.82 [0.44-1.52] 8/383 3/376 18% improvement 2 molnupiravir COVID-19 recovery results c19mp.com Dec 3, 2021 Tau​2 = 0.13; I​2 = 54.4%; Z = 0.64 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 49% 0.51 [0.22-1.18] viral+ 10/118 9/54 Improvement, RR [CI] Treatment Control Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Tau​2 = 0.00; I​2 = 0.0% Early treatment 57% 0.43 [0.32-0.58] 48/293 102/234 57% improvement All studies 57% 0.43 [0.32-0.58] 48/293 102/234 57% improvement 2 molnupiravir COVID-19 viral clearance results c19mp.com Dec 3, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 5.61 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Merck (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tau​2 = 0.24; I​2 = 53.7% Early treatment 55% 0.45 [0.24-0.85] 54/1,407 129/1,317 55% improvement All studies 55% 0.45 [0.24-0.85] 54/1,407 129/1,317 55% improvement 5 molnupiravir COVID-19 Randomized Controlled Trials c19mp.com Dec 3, 2021 Tau​2 = 0.24; I​2 = 53.7%; Z = 2.47 Effect extraction pre-specified Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] 0/140 1/62 Improvement, RR [CI] Treatment Control Merck (RCT) 89% 0.11 [0.01-0.86] 1/709 9/699 Tau​2 = 0.00; I​2 = 0.0% Early treatment 86% 0.14 [0.02-0.78] 1/849 10/761 86% improvement All studies 86% 0.14 [0.02-0.78] 1/849 10/761 86% improvement 2 molnupiravir COVID-19 RCT mortality results c19mp.com Dec 3, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.25 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Improvement, RR [CI] Treatment Control Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Tau​2 = 0.90; I​2 = 82.2% Early treatment 37% 0.63 [0.15-2.69] 15/383 26/376 37% improvement All studies 37% 0.63 [0.15-2.69] 15/383 26/376 37% improvement 2 molnupiravir COVID-19 peer reviewed trials c19mp.com Dec 3, 2021 Tau​2 = 0.90; I​2 = 82.2%; Z = 0.62 Effect extraction pre-specified Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Fischer (RCT) 65% 0.35 [0.01-8.33] death 0/55 1/62 Fischer (RCT) 67% 0.33 [0.01-8.03] death 0/62 1/62 Fischer (RCT) 58% 0.42 [0.02-10.0] death 0/23 1/62 Fischer (RCT) -33% 1.33 [0.14-12.5] hosp. 3/140 1/62 Fischer (RCT) -13% 1.13 [0.07-17.6] hosp. 1/55 1/62 Fischer (RCT) -100% 2.00 [0.19-21.5] hosp. 2/62 1/62 Fischer (RCT) 58% 0.42 [0.02-10.0] hosp. 0/23 1/62 Fischer (RCT) 49% 0.51 [0.22-1.18] viral+ 10/118 9/54 Fischer (RCT) 89% 0.11 [0.01-0.86] viral+ 1/53 9/54 Fischer (RCT) 30% 0.70 [0.25-1.93] viral+ 5/43 9/54 Fischer (RCT) -9% 1.09 [0.37-3.18] viral+ 4/22 9/54 Fischer (RCT) 92% 0.08 [0.01-0.62] viral+ 1/117 6/54 Fischer (RCT) 92% 0.08 [0.00-1.34] viral+ 0/53 6/54 Fischer (RCT) 91% 0.09 [0.00-1.48] viral+ 0/42 6/54 Fischer (RCT) 59% 0.41 [0.05-3.20] viral+ 1/22 6/54 Fischer (RCT) 30% 0.70 [0.37-1.36] viral+ 19/137 12/61 Fischer (RCT) 62% 0.38 [0.13-1.12] viral+ 4/53 12/61 Fischer (RCT) -8% 1.08 [0.54-2.18] viral+ 13/61 12/61 Fischer (RCT) 56% 0.44 [0.11-1.83] viral+ 2/23 12/61 Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Hetero (RCT) 33% 0.67 [0.54-0.82] recov. time 371 (n) 370 (n) Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Khoo (RCT) -100% 2.00 [0.28-14.2] no recov. 4/12 1/6 Khoo (RCT) -100% 2.00 [0.90-4.43] no recov. 4/4 3/6 Khoo (RCT) 0% 1.00 [0.28-3.54] no recov. 2/4 3/6 Khoo (RCT) 0% 1.00 [0.28-3.54] no recov. 2/4 3/6 Khoo (RCT) -50% 1.50 [0.13-17.7] no recov. 1/4 1/6 Khoo (RCT) -200% 3.00 [0.39-23.1] no recov. 2/4 1/6 Khoo (RCT) -50% 1.50 [0.13-17.7] no recov. 1/4 1/6 Merck (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Merck (RCT) 30% 0.70 [0.49-0.99] hosp./death 48/709 68/699 Merck (RCT) 94% 0.06 [0.00-0.97] hosp./death 0/37 9/47 Merck (RCT) 50% 0.50 [0.20-1.26] hosp./death 6/75 13/82 Merck (RCT) 24% 0.76 [0.42-1.38] hosp./death 18/237 22/221 Merck (RCT) 42% 0.58 [0.20-1.68] hosp./death 5/47 7/38 molnupiravir COVID-19 outcomes c19mp.com Dec 3, 2021 Favors molnupiravir Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit